
    
      This is a dose-escalation study of autologous anti-CD123 CAR-T cells. Patients receive
      fludarabine phosphate(300 mg/m^2) and cyclophosphamide (30 mg/m^2) IV on days -5 to -3, and
      then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of
      total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the
      side-effects occured). The total dose of CAR-T cells used in dose-escalation study is
      0.5x10^6- 2.0x10^6 CAR-T cells/kg.
    
  